SUNPHARMA

is evaluating the acquisition of US-based Organon, a women’s health and biosimilars specialist, in a deal valued at about $10 billion. Organon had debt of $8.9 billion at end-Q2 2025 and Q3 revenue of $1.60 billion. If completed, it would significantly strengthen Sun’s US presence and mark the largest cross-border acquisition in India’s pharma sector.